Analysis Tools
immune system
|
• embryos exposed to tamoxifen at E10.5-12.5 show some blood-filled dermal lymphatic vessels
• embryos exposed to tamoxifen show reduced number of superficial vessels (X-gal stained); severity of reduction increases with early tamoxifen treatment
• tamoxifen treatment at E10.5 or E11.5 results in severely reduced lymphatic endothelial cell numbers and lack of lymphatic vessels
• embryos exposed to tamoxifen at E10.5 or 11.5 display drastically mispatterned lymph sacs that are reduced in size compared to controls
• when tamoxifen exposure occurs at E13.5, few embryos show any lymphatic defects, while exposure later in development or postnatally causes no obvious defects despite reduction in Nr2f2 expression in LECs
|
homeostasis/metabolism
